• FDBL announces new artist acquisition: Remy Boy Monty
• Fan Pass capable of satisfying fans’ overwhelming appetite for content while providing new revenue streams for Monty
• Monty opens up potential for signing additional artists

With the focus of connecting and engaging users, the mobile tech and marketing company Friendable (OTC: FDBL) launched its platform Fan Pass Live in July 2020. In November, the company announced a new artist acquisition: Remy Boy Monty (https://ibn.fm/odUSn). The live-streaming platform Fan Pass is FDBL’s flagship offering designed to help artists engage with their fans around the world and earn revenue from live-streaming performances, merchandise sales and fan subscriptions. The Fan Pass platform supports artists at all levels, creating exclusive artist channels based on their particular music genre. When in-person performances re-emerge, Friendable intends to allow fans exclusive access to VIP, Meet & Greet, and Backstage experiences as well. Today fans across the world have an overwhelming appetite for content; this platform can satiate that need. Montana “Monty” Bucks, aka Remy Boy Monty, was introduced to FDBL’s Fan Pass platform before the launch, but the timing was not right. Now it is, and Monty is ready to grow and engage his fans while creating new revenue streams worldwide through Fan Pass. “Having met the Remy Boy team prior to our launch, I was hopeful of the opportunity to bring him onto the Fan Pass platform, and now that time has come only a few short months later,” said Friendable CEO Robert A. Rositano Jr. “Myself, our management team and Fan Pass agents in general are excited to have Remy Boy on our platform, and his channel is being built for release just as soon as we receive graphic sign-off and the proper approvals regarding the look of his artist channel.” Remy Boy Monty and his childhood friend Willie “Fetty Wap” Maxwell, co-founded the rap troupe Remy Boyz 1738. Monty is now CEO of the company and its record imprint. Artists on the imprint include Fetty Wap and Chaos and Tap. Remy Boyz has a large following with approximately 435,000 Instagram followers, 1,827 monthly Spotify listeners and more than 23,000 YouTube subscribers. Monty officially launched his first solo album in June 2015, selling more than 1 million domestic copies, with one single from the album reaching No. 2 on the U.S. Rap Songs Chart. In it’s first six months, the single’s video gained 100 million views on YouTube. Monty has appeared on “The Tonight Show Starring Jimmy Fallon” and toured with Fetty Wap and opener Post Malone on the “Welcome to the Zoo” tour. Monty and Wap have a collaborative track, “My Way,” which was nominated at the BET Hip Hop Awards for Best Collaboration, Duo or Group in 2015. The album reached No. 1 on the U.S. Billboard 200, No. 2 on the U.K. R&B Albums, and surpassed No. 15 in Australia, Canada and Sweden. Monty’s addition to Fan Pass opens up more artist possibilities. The Remy Boyz have been highly successful, and as Fan Pass continues to grow, FDBL looks forward to the potential of bringing more of them to the platform. “It’s amazing to have an artist like Remy Boy,” said Rositano, “who just happens to have started out with another artist we have had the pleasure of working with in the past on another project (Fetty Wap), whom we hope to see on Fan Pass in the near future as well.” The Fan Pass Platform was launched as a solution for artists looking to increase revenue streams during the COVID-19 pandemic and associated shutdowns. For more information, visit the company’s website at www.Friendable.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Data have shown that even open, public spaces are not exempted when it comes to criminal activity that can be threatening or harmful to others
• Tech pioneer Knightscope has created self-driving security robots that can safely patrol indoor and outdoor public areas, helping to deter crime and collect important information in the process
• The company’s CEO will be interviewed by IPO and hedge fund managers during a virtual fireside chat event Dec. 9 to talk about MaaS solutions in the security field
• Knightscope is not listed on a public exchange, but its shares are available for purchase through its Reg A+ offering
• The company’s production lineup includes a stationary machine, an indoor robot and an outdoor robot sentry that are equipped with features such as 360-degree eye-level HD streaming video, people detection and facial recognition features, automatic license plate recognition, thermal anomaly detection, and automatic signal detection

The National Crime Victimization Survey (“NCVS”), which obtains data each year from crime victims about the circumstances of the incident, noted in a report on the location of criminal incidents between 2004 and 2008 that at the time almost 1 in 5 violent crimes took place in open areas such as yards, playgrounds, fields, on the street or in other similar locations, and almost 1 in 5 violent crimes took place in open areas such as yards, playgrounds, fields, on the street or in other similar locations (https://ibn.fm/EKTdD). While more up-to-date data isn’t available, data from even 15 years ago demonstrate real-life concerns about the potential for crimes to occur even in public locations. Knightscope, an autonomous security robot (“ASR”) developer based in California’s Silicon Valley, has built its technologies from the ground up in response to the nation’s safety needs and with an eye on cost-competitive solutions. Knightscope’s sentinel solution to crime detection and prevention includes its lineup of K1 stationary machines, K3 indoor machines and K5 outdoor machines. The artificial intelligence-enhanced sentries are designed to record a tremendous amount of information while serving as a crime deterrent in function simply by being present. The roving machines can also communicate using recordings or live-transmitted messages. In the process, they present a non-threatening security patrol that is nonetheless a capable deployment in combating criminal activity on the front lines. The sentries have already been credited with helping investigators to solve crimes and with helping to reduce the amount of criminal activity some public places such as parking lots experience. They have also helped detect a heat spike before a fire erupted. Clients include hospitals, Fortune 1000 companies, law enforcement agencies and most recently the federal government’s Veterans Administration (https://ibn.fm/7Z26X). Knightscope will discuss its vision for the Machine-as-a-Service (“MaaS”) industry in a fireside chat Wednesday, Dec. 9 at 2 p.m. EST. The event will last about an hour with time for questions from the virtual audience, hosted by IPO Edge in partnership with The Palm Beach Hedge Fund Association, a Florida trade association for financial professionals and ultra high net worth investors (https://ibn.fm/J4GUd). Knightscope is not publicly traded on national exchanges, but its shares are open to purchase by the public all the same through its Reg A+ offering. “A lot of larger institutional investors will say, … ‘You have 7,000 investors, they must be driving you mad,’” CEO William Santana Li said during an interview earlier this year with StartEngine strategic adviser Kevin O’Leary, aka Mr. Wonderful (https://ibn.fm/tzw76). “I tell them, ‘Listen, chief security officers of major corporations are investors of ours. NYPD detectives, FBI, CIA, DHS, vice presidents of leasing of major malls. I would never dare trade out our 7,000 investors for three or four guys (it’s mostly guys) sitting around a table asking the wrong questions, worried about all the wrong things.”  As of this writing, investors backing Knightscope now top well in excess of 16,000. For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• SGTM engaged Anthony L.G., PLLC to initiate FORM-10 process to become fully reporting, assist with SEC legal issues and uplist to NASDAQ
• SGTM produces environmentally beneficial products using natural waste created by hurricanes and storms while preventing burdens on municipal landfills
• Clients include The Kroger Co., Circle K, 7-Eleven, Menards Inc., Old Castle Lawn & Garden, large retailers and municipalities
• SGTM recorded 794% increase in revenue, 4,817% increase in gross profit for first half of 2020 when compared to all of 2019

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, has engaged Anthony L.G., PLLC to initiate the FORM-10 process to become fully reporting, assist with all SEC legal matters, and uplist to the NASDAQ. The engagement was made following a highly successful year for the company, marked by a string of lucrative contracts that included agreements with The Kroger Co., Circle K, 7-Eleven, Menards Inc., Old Castle Lawn & Garden, and more. “We have communicated with many firms since our audit completion to see who would be best suited for our team, shareholders, and to transpire our vision,” said SGTM CEO and Director Tony Raynor. “After communicating with Laura Anthony and doing our due diligence, our team feels more confident than ever on achieving our ultimate goal to be listed on the NASDAQ.” In preparation for the FORM-10 process, SGTM completed audits for the two years ending December 2018 and 2019 at the end of October this year. Business results for the company have been impressive, resulting primarily from its successful growth strategy based on providing solutions to organic waste burdens created by storms and hurricanes in the United States. Rather than allow tree debris and other natural waste to burden municipal landfills, SGTM transforms this resource into organic next-generation products that benefit the environment such as garden mulch and certified playground surface material. The company grew significantly in 2020 as a result of new national partnerships, strategic acquisitions and organic growth strategies resulting in new revenue streams and contracts. In anticipation of its future uplisting, the company recently reported remarkable financial results that include a 794% increase in revenue and a massive 4,817% increase in gross profit during the first half of 2020 when compared to all of 2019 (https://ibn.fm/cKI9h). SGTM offers synergistic solutions that benefit the environment while offering investors an excellent opportunity to purchase shares in a sustainable business with promising growth potential. The importance of ethical investing appears to be trending upwards, evidenced by surveys of millennials that suggest that the majority would accept lower returns if an investment was sustainable (https://ibn.fm/WHuKa). SGTM provides that opportunity, driven forward by its expert management team that continues to fulfill the company mission while expanding operations and diversifying revenue streams amid increased demand for sustainable solutions to serious environmental issues. To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/YTjPF. NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• David Elliott, industry veteran and member of Canadian Mining Hall of Fame, cites right people, right science as key factors to mining success
• Elliott finds certain jurisdictions, including Canada and South America, compelling mining locations
• Led by industry-seasoned professionals and operating in Canada and Chile, GoldHaven Resources appears well positioned to respond to mining investors’ demands

During an interview at the recent Global Mining Symposium, David Elliott, a new member of the premier Canadian Mining Hall of Fame, noted that the right people and the right science are critical elements that investors look at when determining which mining companies to invest in (https://ibn.fm/haIyD). GoldHaven Resources (CSE: GOH) (OTCQB: ATUMF), a junior mining company lead by an executive team with significant mining and scientific experience, is well equipped with strengths investors seek when making decisions about capital placement. Elliott is a founding partner at Haywood Securities, a company he built from a small firm into a major merchant bank with around $10 billion of assets under management. He is also a mining veteran who has backed more than 400 junior mining exploration companies. As a seasoned industry professional with a proven track record of success, he is adamant that two things are essential for investing in the mining space: the right people and the right science. “To me, it always boils down to people” he said during the interview. “I’ve always focused on backing intelligent science, so I always wanted to partner with geoscientists that have strong technical skills, who spent a lot of time in the field, mapping, have worked in different geological environments and have a passion for discoveries.” With more than 30 years of mining experience, Elliott noted that geologically endowment is not the be-all and end-all of success in the industry. Some jurisdictions, although geologically endowed, may not be in mining-friendly countries where mining companies can get social acceptance and a permit to mine. “The world is shrinking where you want to put your investment dollars,” he explained. “North America, Canada is a good place. I think Australia has the geology and you can build a mine. There are a few places in South America that can deliver. Colombia is an interesting geological setting where you have these deep-seated intersection zones that can create sizeable deposits.” As a Canadian junior mining company lead by an experienced team and active in the Maricunga Gold Belt in Northern Chile and Adam West in British Columbia, Canada GoldHaven Resources appears well-positioned to respond to today’s mining investors’ demand. GOH’s executive team includes CEO Daniel Schieber. Schieber established his career in metals and mining finance as an analyst for the Stabilitas Group of Funds. He also co-founded Euroscandic International Group, raising an estimated $350 million in project financing for development projects in the mining sector. Other key team leaders include David Smith, president, co-founder and director David Smith, who has been closely aligned with corporate development of a number of mining companies in South America for more than eight years; head of exploration and director Patrick Burns, a Canadian geologist with over 40 years of experience; director Gordon Ellis, a professional engineer and entrepreneur with more than 50 years of experience in mining and resource development; and Scott Dunbar, who has decades of experience as a geologist worldwide and presently is the department head of Mining Engineering at the University of British Columbia. As a company well-positioned to leverage key mining strengths required in today’s business environment, GoldHaven Resources may offer compelling value potential for investors seeking to invest capital in the sector. For more information, visit the company’s website at www.GoldHavenResources.com. NOTE TO INVESTORS: The latest news and updates relating to ATUMF are available in the company’s newsroom at http://ibn.fm/ATUMF

• Biotechnology developer CNS Pharmaceuticals is preparing, with its partner WPD Pharmaceuticals, a global set of Phase 2 trials for its drug candidate Berubicin, which has shown promise in combating the effectively fatal glioblastoma multiforme (“GBM”) brain cancer
• Since another company conducted Phase 1 safety trials for Berubicin 14 years ago, one patient has survived cancer-free while two others saw reductions in tumor size of up to 80 percent
• The Phase 2 trials will build on the Phase 1 results, conducting targeted testing that offers side-by-side comparison between Berubicin and chemotherapy drug lomustine in real time beginning next year
• The company is also preparing with WPD to conduct the first Phase I trials of Berubicin in children in Europe
• CNS Pharmaceuticals officers recently participated virtually in the annual Society for Neuro-Oncology (“SNO”) Scientific Meeting and Education Day to promote their work and discuss the progress of clinical trials

While the world’s attention remains occupied with developments related to the global coronavirus pandemic that has infected about 60 million people and claimed the life of nearly 1.5 million of them (https://ibn.fm/ki9Vf), a dedicated group of researchers continues to pursue breakthroughs on the nearly always fatal glioblastoma multiforme (“GBM”) type of brain cancer. Recently, the Society for Neuro-Oncology (“SNO”) held its 25th Annual Scientific Meeting and Education Day to spotlight the efforts of over 2,600 researchers and clinician scientists from more than 40 countries in researching and treating GBM and similar brain cancers (https://ibn.fm/WCLpE). CNS Pharmaceuticals (NASDAQ: CNSP) appeared at the virtual conference through a joint sponsorship with WPD Pharmaceuticals, staffing a booth in the virtual exhibit hall while Dr. Patrick Wen, a member of CNS’s Science Advisory Board, participated in a panel discussion on clinical trials during the plenary session Nov. 20, and in online poster presentations throughout the three-day event (https://ibn.fm/L99MV). CNS Pharmaceuticals is preparing to launch a Phase 2 trial of its leading drug candidate, Berubicin, an anthracycline that has demonstrated significant potential in appearing to effectively cross the blood-brain barrier and effectively targeting central nervous system malignancies. The medical science companies presenting their progress toward a more effective treatment of glioblastomas at the SNO conference generally focused on the safety and tolerability of using their drug candidates in animals or early-stage human trials. CNS appears to have an advantage in that Berubicin not only demonstrated safety in the Phase 1 trials conducted by another company 14 years ago; the clinical benefit response of stable disease or better was 44 percent with one patient who still remains alive and cancer-free and another two patients whose tumors shrunk by up to 80 percent. CNS has obtained Orphan Drug Designation (“ODD”) for Berubicin in treating malignant gliomas and announced Nov. 17 that it has now filed an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) which has been accepted for review (https://ibn.fm/C99tn). The company’s Phase 2 trial will recruit 243 patients for side-by-side, real-time analysis of Berubicin’s performance against the chemotherapy standard of care drug lomustine. The trials will take place on a global scale, administering Berubicin to 162 tumor patients and Iomustine to the other 81 in about 60 study centers scattered across North America, Europe and the Asia-Pacific region, company officers said in a November webinar (https://ibn.fm/pbPBn). “We are evaluating responses defined as a decrease in the size of the tumor, as well as stability of the disease defined as no further increases in the size of the tumor once the patient is put on study, as well as the time to progression of these tumors and importantly overall survival of the patients,” CMO Dr. Sandra Silberman said during the webinar. Existing treatments mostly avail themselves of surgery and the drug temozolomide, which has been shown effective in temporarily extending the lifespan of fewer than 40 percent of GBM patients with a specific genetic variation. But overall, glioblastoma patients have a median survival rate of only 14.6 months from the date of the malignancy’s diagnosis as the cancer recurs and resists new interventions — a significant reason why the Berubicin trial participant’s survival for 14 years without cancer is so exciting. CNS expects the trial enrollment to take two to two and a half years with funding occurring in stages as critical benchmarks are achieved. CEO John Climaco said the trial could potentially lead Berubicin toward an expedited regulatory pathway, which would save time and money in the long run. CNS is also simultaneously pursuing a first-ever Phase I Berubicin safety trial in Poland for children who have the GBM tumor and have run out of other medical options. This trial is being conducted by WPD Pharmaceuticals, a CNS sub-licensee. For more information, visit the company’s website at www.CNSPharma.com NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Financial report notes working capital of $44.7 million at end of Q3 2020, increase of 17% over Q2 2020
• Key quarter highlights include becoming debt-free, progress on rare earth elements (“REEs”)
• CEO reports company making “significant strides in the last quarter on our uranium, rare earths and other initiatives”

Energy Fuels (NYSE American: UUUU) (TSX: EFR) has released its financial results for the quarter ended Sept. 30, 2020, as well as a corporate update (https://ibn.fm/dZn68). In addition to being debt free, the report noted that the company had working capital of $44.7 million at the end of Q3 2020, which is an increase of 17% over Q2 2020. The working capital included $28.1 million in cash and marketable securities, plus $25.6 million of concentrate inventory and work in progress. Following the end of the quarter, the company retired all of its outstanding debt. Another key quarter highlight for Energy Fuels includes being selected by the U.S. Department of Energy (“DOE”) to develop a design for the production of a rare earth element (“REE”) concentrate from coal-based resources. The company will work with a team from Penn State University on the project. Energy Fuels’ management team anticipates that the REEs contained in these coal-based resources are similar to the REEs contained in other ores it is currently evaluating in its REE program. “Energy Fuels made significant strides in the last quarter on our uranium, rare earths and other initiatives,” said Energy Fuels president and CEO Mark S. Chalmers. “On the uranium front, we were pleased to see the U.S. Department of Commerce successfully extend the Russian Suspension Agreement. . . On the REE front, we are making excellent progress. We are currently conducting pilot-scale testing on ore sources at the White Mesa Mill, which is confirming our ability to produce an on-spec rare earth concentrate at a commercial level, along with the uranium from the ore. We are also in discussions with various parties in North America regarding rare earth/uranium ore sources for the Mill and potential purchase of our finished rare earth concentrate.” As Chalmers mentioned, in September, the U.S. Department of Commerce announced it had obtained Russia’s agreement to extend limits on uranium imports into the United States. The extended Russian Suspension Agreement (“RSA”) was finalized in October. The expiration of the RSA, originally scheduled for the end of 2020, could have resulted in unlimited quantities of Russian uranium imports into the United States. The extension of the limits provides long-term support of the U.S. uranium mining industry. Energy Fuels’ ability to achieve a debt-free status marks a significant accomplishment (https://ibn.fm/0huC3). “While many uranium and other natural resource companies have significant debt burdens, Energy Fuels is proud to announce that today we became debt free,” said Chalmers. “Being debt-free distinguishes Energy Fuels not only from many of our peers in the uranium and natural resource sectors but also from many public companies in general. Having no debt reduces costs and allows Energy Fuels to better weather market volatility. Coupled with our strong working capital position, this also provides us with a ‘clean slate’ from which to increase uranium production when warranted and to launch the exciting rare earth element initiative we are pursuing. We have a number of opportunities in front of us right now, any one of which could result in significant cash flows for the company.” Energy Fuels is the number-one U.S. producer of uranium. The company was also the top U.S. producer of vanadium in 2019 and is conducting pilot-scale testing to potentially begin producing a rare earth element concentrate at its White Mesa Mill as soon as Q1-2021. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today. The Nichols Ranch ISR Project is fully licensed, constructed and on standby, and licensed to produce 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also fully licensed, constructed and on standby, and licensed to produce 1.5 million pounds of U3O8 per year. For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• Demand for copper is rising; deficit forecast in coming years
• Copper deficit heightens need for projects that can produce the high-demand metal
• Feasibility study concluded that Josemaria’s average annual metal production of 136,000 tonnes of copper (“Cu”), 231,000 ounces of gold (“AU”), 1,164, 000 ounces of silver (“Ag”)
• Strategic plan demonstrates commercial production at project could be achieved by early 2026

The looming copper deficit will likely worsen in the coming years, according to an S&P Global Market Intelligence report (https://ibn.fm/OSonS). That news is capturing the attention of companies such as Josemaria Resources (TSX: JOSE) (OTCQB: JOSMF), a Canadian natural resources company focused on the development of its wholly owned Josemaria copper-gold mining project.

“A deficit in the copper market is set to deepen over the next several years as supply of the widely used metal struggles to keep up with strong demand from the power and construction sectors, compounded by the proliferation of electric vehicles,” reported the S&P article, which was titled “Copper supply faces struggle to keep up with growing demand.” The article noted that refined output is expected to increase by 4.3% year on year to 24.7 million tonnes in 2021 after decreasing by 2.1% to 23.6 Mt in 2020—primarily as a result of disruptions caused by the coronavirus pandemic.

Highly attuned to market demands, Josemaria Resources is working to develop its flagship property — the Josemaria Copper-Gold Project — as quickly as possible. The project is located in the San Juan Province of Argentina, a well-known mining hub supporting a wide variety of mining and service companies.

Josemaria just recently announced the results of an independent feasibility study evaluating the property (https://ibn.fm/6BmVS). In short, the study concluded that the property is a “robust, rapid pay-back, low-risk project, with an open-pit operation feeding a conventional process plant at 152,000 tonnes per day over a 19 year mine life, yielding average annual metal production of 136,000 tonnes of copper (‘Cu’), 231,000 ounces of gold (‘Au’) and 1,164,000 ounces of silver (‘Ag’).”

“We are extremely pleased with the results of the Feasibility Study at Josemaria, which indicates that this is one of the very few readily developable copper-gold projects in the world today,” said Josemaria Resources president and CEO Adam Lundin. “This study has materially de-risked the project and forecasts an attractive economic outcome, which is comparable with other large-scale copper/gold projects already being developed or in production today. We believe that Josemaria is perfectly positioned to commence production by mid-decade, meeting rising copper demand from a rapidly electrifying global economy. I believe the study results will allow us to unlock various financing opportunities as we move toward construction.”

Josemaria Resources has already begun a bridging phase of engineering, which will be followed by the initiation of basic engineering planned for early 2021. The company’s clear and achievable project execution plan and its strong industry position demonstrate commercial production at the project could be achieved by early 2026, ideally timed to meet the growing copper deficit (https://ibn.fm/QxuPj).

Josemaria Resources is a Canadian natural resources company based in Vancouver, British Columbia. The company is part of the Lundin Group of companies, a conglomerate of 13 business entities operating in the mining, oil and gas and renewables sectors around the world.

For more information, visit the company’s website at www.JosemariaResources.com.

NOTE TO INVESTORS: The latest news and updates relating to JOSMF are available in the company’s newsroom at https://ibn.fm/JOSMF

• VTGN CEO “even more excited about PH94B’s potential to change lives without the risky side effects and safety concerns of benzos”
• Study results suggest PH94B’s mechanism of action may not have benzodiazepine-like side effects, such as sedation, cognitive impairment or abuse liability
• Company making significant progress in preparing PH94B for launch of pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder

VistaGen Therapeutics (NASDAQ: VTGN) has reported new preclinical findings differentiating the mechanism of action of PH94B from that of benzodiazepines (https://ibn.fm/Al4ur). PH94B is an intranasal neuroactive steroid VistaGen is preparing for Phase 3 development as a potential acute rapid-onset treatment of anxiety in adults with social anxiety disorder. As a solution to anxiety notably lacking the notorious side effects of traditional medications, the formulation could be a game-changer to the world of mental health.

“We are very pleased with the results of these studies that suggest PH94B’s mechanism of action may not have benzodiazepine-like side effects, such as sedation and cognitive impairment, or abuse liability,” said VistaGen CEO Shawn K. Singh. “While benzodiazepines provide relief for many Americans struggling with anxiety, the extremely risky safety profile does not lend itself to long-term use. The mechanism of action contributes to the safety profile.”

VistaGen, a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, reported that new in vitro electrophysiology data demonstrating that PH94B’s mechanism of action does not involve direct activation of GABA-A receptors. That is in direct contrast to the mechanism of action of benzodiazepines (benzos), which act as direct positive modulators of GABA-A receptors.

“As we have seen in Phase 2 clinical studies, while PH94B is able to produce rapid-onset benzo-like, anti-anxiety effects, this study demonstrates that PH94B does not have a benzo-like mechanism of action,” noted Singh. “As we approach Phase 3 development of PH94B, especially given the FDA’s recent public announcement about safety concerns associated with benzo use, these new data make us even more excited about PH94B’s potential to change lives without the risky side effects and safety concerns of benzos.”

In additional news, VistaGen also provided business updates and released its financial results for the fiscal 2021 second quarter ended September 30, 2020 (https://ibn.fm/kBQkL). Key highlights for the company included a positive FDA meeting that outlined the pathway to a key PH94B Phase 3 study beginning recruitment Q2 2021, along with news that the company had received more than $17.5 million in net proceeds from a public offering of common stock and a PH94B upfront license payment. The company also noted positive new data had been gathered from its second preclinical study of AV-101 in combination with probenecid.

“We see a significant rise in mental health concerns as the global COVID-19 pandemic continues to impact the daily lives of millions of individuals,” observed Singh. “We are committed to developing innovative therapies that provide relief to those suffering from anxiety and depression, and we are working diligently towards that goal.

“We are making significant progress in preparing PH94B for launch of a pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder in the second quarter of 2021,” he continued. “After reaching consensus with the FDA on the key components of the study design, it will be very similar to the statistically significant Phase 2 study of PH94B in social anxiety disorder. We are also working with the FDA to finalize details for our Phase 2A study of PH94B in adjustment disorder, which we are planning to initiate in early 2021.”

VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date and therapeutic potential in multiple CNS markets.

For more information, visit the company’s website at www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

• NETE plans to divest payments processing model to enter EV industry through proposed merger with privately-held Mullen Technologies Inc.
• Merger allows Mullen stakeholders to obtain majority of stock while accelerating process of taking company public, funding US expansion
• Mullen accepting reservations for Dragonfly K50 sports car and MX-05 SUV, production for both projected to start in 2021
• California-based Mullen subsidiaries include Mullen Energy, Mullen Auto Sales, Mullen Finance Corp., CarHub digital marketplace

Future generations may look back and wonder how humanity withstood the exhaust fumes, noise and environmental degradation created by fossil fuel engines. The downsides of combustible engines, rising fuel prices and positive government incentives are all factors driving EVs into the mainstream – and some experts predict purely electric models will surpass hybrids during the transition. Net Element (NASDAQ: NETE), through its proposed merger with Mullen Technologies, is planning to divest its payments processing business model to enter the burgeoning EV industry. The strategic move will allow the stakeholders of privately held Mullen to gain a majority of the new stock while catalyzing the process of taking the company public and accelerating its expansion in the United States. The bold move comes at a time of rapid industry expansion amid growing concern for the environment among the general public and policy-makers. Falling battery prices, government mandates and consumer incentives are propelling the industry forward, prompting some industry experts to predict that the pure electric models will surpass hybrids within the next few years as the transition takes place. “I think we’ll see a faster transition to pure EVs,” said Dane Parker, an industry executive and participant at Business Insider’s IGNITION: Transportation virtual event (https://ibn.fm/cJ470). Besides his belief that hybrids are more complex to engineer, Parker predicts that by 2025 battery prices will have dropped substantially, resulting in the accelerated adoption of pure electric vehicles and their eventual dominance over hybrids. Through its subsidiaries that include Mullen Auto Sales, Mullen Finance Corp., a digital marketplace called CarHub and battery-focused Mullen Energy, Mullen Technologies has already made significant headway in the US. Among the company’s expansion plans is the production of the Dragonfly K50 luxury electric sports car at its new proposed 1.3 million square-foot assembly and manufacturing space in Spokane, Washington. Featuring a Rechargeable Energy Storage System (RESS), the Dragonfly boasts a range of up to 310 miles and can accelerate from 0-60 miles/hour in under 4.2 seconds. Limited to only 1000 units, the company has started accepting reservations with production set to begin next year. Pre-orders for another Mullen vehicle – the five-passenger MX-05 – have also begun. Production for the pure electric all-wheel SUV is set to begin in 2021 with deliveries set for mid-2022. Starting at $55,000, the MX-05 boasts a range of 325 miles on a single charge and can hit 60 miles/hour from zero in just 3.2 seconds. Formerly a global financial technology and value-added solutions group, NETE plans to leverage the increased demand for electric vehicles through a proposed merger with Mullen Technologies. Based in California, Mullen Technologies engages in electric vehicle manufacturing across an international distribution network, partnering with several original equipment manufacturers across the world to provide exciting EV options for the US market. For more information, visit the company’s website at www.NetElement.com. NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

• Denver-based HempFusion Wellness, Inc. has developed 46 products and 8 OTC FDA listed topicals that draw on the versatile compounds in hemp for promoting effective sleep, stress reduction, pain relief, skin care and “smooth energy” pick-me-ups
• Despite a downturn in the hemp and CBD product industries brought on by the worldwide COVID-19 pandemic, HempFusion is anticipating a market rebound amid positive developments in legal, political and medical research arenas
• Market analysts at Brightfield Group anticipate improvement in the CBD sector to $12.4 billion by 2023 and $16.8 billion by 2025
• HempFusion has filed a preliminary prospectus for a planned initial public offering of its stock in Canada and a listing on the Toronto Stock Exchange under the symbol CBD.U

Legal cannabis consumers have already become well aware of the hammering the industry has taken during the COVID-19 era. Market outlooks have been revised sharply downward as many retailers selling CBD products have closed temporarily or transitioned to curbside pickup and delivery, and farmers have reduced their hemp acreage. But nearly a year into the global pandemic, there have been bright spots as well. While the health crisis has impacted product movement, the legal front lines continue to advance. The European Union’s highest court declared this month that cannabidiol (“CBD”) is not a narcotic drug, despite some EU countries’ efforts to control it on such health-related grounds (https://ibn.fm/wRR8o). In the United States, the presidential elections delivered an apparent victor who favors decriminalization of marijuana, if not outright legalization, while additional states joined the drive toward relaxed legislation within their boundaries (https://ibn.fm/nTFxP). And pandemic-related stress is credited with driving sales increases in some areas (https://ibn.fm/Y3CnJ). CBD brand HempFusion Wellness is optimistic about renewed energy in the marketplace, mirroring its products’ aim to help restore energy and wellness balances to its consumers. “Researchers have newly discovered a system inside of our body that has been affectionately named the endocannabinoid system,” CEO Jason Mitchell explains in a video outlining the company’s operations (https://ibn.fm/DkCCn). “What’s really special about it is that in this identification they have found an intricate network of receptors located throughout the entire body that interconnect all of the biological systems together. They’ve deemed it a regulatory system because it helps to maintain and support homeostasis or balance inside the body.” Mitchell notes that hemp is plant source of cannabinoids that may interact with the body’s system, citing the company’s varied products as able to promote effective sleep, stress reduction, pain relief, skin care and “smooth energy” via liquid tinctures and taste-free liquid capsules, thanks in part to their full-spectrum delivery and combination with other natural elements, such as adaptogen herbs. “The name HempFusion means hemp fused together with other products,” Mitchell states. Researchers at market analysis firm Brightfield Group forecast a CBD marketplace worth $10 billion this year and $23 billion by 2023 before the pandemic swept the planet. They have since revised their outlook downward to $12.4 billion by 2023 and $16.8 billion by 2025 (https://ibn.fm/ZZ3vX). However, the rapid-response effort to deliver a potential COVID-19 vaccine has led some media outlets to predict the end of the pandemic is in sight (https://ibn.fm/kgK3d), which could open the gates to a restored sense of excitement about world economic recovery and CBD products’ return to previous expectations if the relatively new technology of mRNA-based vaccines proves sustainable. HempFusion has developed 46 products and announced last month that it has produced a preliminary prospectus with securities regulatory authorities in Canada for a proposed initial public offering that could land its common shares in all of the provinces but Quebec as it lists on the Toronto Stock Exchange. That makes HempFusion the first U.S.-based CBD company to apply to list on the TSX (https://ibn.fm/n7GXD). For more information, visit the company’s website at www.HempFusion.com/Corporate-Information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/HempFusion